ACORN BIOVENTURES — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies.
BiotechDigital HealthHealthtechMedical DevicesBoulder, US
Jason Leverone(Executive Officer)Samuel Agresta(Executive Officer)Dylan Hartley(Executive Officer)Nicholas Saccomano(Executive Officer, Director)Wendy Johnson(Executive Officer)
Board seatIsaac Manke· per SEC Form D · $65M raise · filed Oct 2024
Co-investorsAccess BiotechnologyRiverVest Venture PartnersAbingworthBoulder VenturesNew Enterprise Associates (NEA)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.